Dermata Therapeutics (DRMA) vs GRI Bio (GRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dermata Therapeutics is the larger company by market cap ($2.5 million vs $2.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRMA | GRI |
|---|---|---|
| Share price | $0.5095 | $1.12 |
| Market cap | $2.51M | $2.45M |
| 1-day change | -4.23% | 0.00% |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-3.28 | $20.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.56M | $-11.96M |
| 52-week high | $4.66 | $64.12 |
| 52-week low | $0.50 | $1.09 |
| Distance from 52-week high | -89.07% | -98.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +685.08% | +1551.79% |
| Average volume | 2.78M | 218.31K |
| Shares outstanding | 4.93M | 2.19M |
| Employees | 9 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dermata Therapeutics
DRMA stock →Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
DRMA vs GRI FAQ
Which is bigger, Dermata Therapeutics or GRI Bio?
Dermata Therapeutics (DRMA) is larger, with a market capitalization of $2.51M compared with $2.45M for GRI Bio (GRI).
Are Dermata Therapeutics and GRI Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.